Scott E. Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Scott E. Johnson has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Danny L. Jue
Scientific Resources Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
1 shared publicationEdwin W. Ades
Division of Bacterial and Mycotic Diseases, Atlanta, Georgia
1 shared publicationGeorge M. Carlone
Division of Bacterial and Mycotic Diseases, Atlanta, Georgia
1 shared publicationJanet K. Dykes
Division of Bacterial and Mycotic Diseases, Atlanta, Georgia
1 shared publicationJaquelyn S. Sampson
Division of Bacterial and Mycotic Diseases, Atlanta, Georgia
1 shared publication
Latest Publications
- Open Access
- 15 February 2002
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 185 (4) , 489-496
Inhibition of Pneumococcal Carriage in Mice by Subcutaneous Immunization with Peptides from the Common Surface Protein Pneumococcal Surface Adhesin A
Pneumococcal surface adhesin A (PsaA), a common protein expressed on all 90 pneumococcal serotypes, is a vaccine candidate. Three anti-PsaAmonoclonal antibody phage display-expressed monopeptides (15 mers), in various formulations as lipidated or nonlipidated multiantigenic peptides or as bi- or tripeptide constructs, were studied in a mouse nasopharyngeal carriage model to determine the inhibitory effect of induced antibodies on carriage of pneumococcal serotypes 2, 4, and 6B. Antibodies to each of the various peptides tested reduced carriage of the 3 serotypes. Reduction in carriage by nonlipidated multiantigenic peptide antibodies was highly variable (39%–94%; mean, 59%; standard deviation [SD], 20.2%); however, more-consistent results were observed in mice immunized with lipidated (56%-98%;mean, 69%; SD, 13.6%) and combination or bipeptide (55%–91%; mean, 76%; SD, 13.1%) formulations. These peptides are immunogenic, and their induced antibodies reduce carriage in mice. PsaA peptides demonstrate potential for being important new vaccines against pneumococcal carriage, otitis media, and invasive pneumococcal disease.
- 15 February 2002
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 185 (4) , 489-496
Open AccessInhibition of Pneumococcal Carriage in Mice by Subcutaneous Immunization with Peptides from the Common Surface Protein Pneumococcal Surface Adhesin A
Pneumococcal surface adhesin A (PsaA), a common protein expressed on all 90 pneumococcal serotypes, is a vaccine candidate. Three anti-PsaAmonoclonal antibody phage display-expressed monopeptides (15 mers), in various formulations as lipidated or nonlipidated multiantigenic peptides or as bi- or tripeptide constructs, were studied in a mouse nasopharyngeal carriage model to determine the inhibitory effect of induced antibodies on carriage of pneumococcal serotypes 2, 4, and 6B. Antibodies to each of the various peptides tested reduced carriage of the 3 serotypes. Reduction in carriage by nonlipidated multiantigenic peptide antibodies was highly variable (39%–94%; mean, 59%; standard deviation [SD], 20.2%); however, more-consistent results were observed in mice immunized with lipidated (56%-98%;mean, 69%; SD, 13.6%) and combination or bipeptide (55%–91%; mean, 76%; SD, 13.1%) formulations. These peptides are immunogenic, and their induced antibodies reduce carriage in mice. PsaA peptides demonstrate potential for being important new vaccines against pneumococcal carriage, otitis media, and invasive pneumococcal disease.